Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4372 CVM-005: A multicentre, single-arm, phase IIa study of CVM-1118, a novel oral anti-vasculogenic mimicry (VM) agent, in patients with treatment-refractory advanced neuroendocrine tumours (NET)

Introduction: NETs are highly vascularised tumours and a viable target for anti-VM therapies. CVM-1118 is an anti-tumour agent with multiple MOAs, including disruption of VM networks and induction of apoptosis via targeting mitochondrial TRAP1 protein.

Conference:

Presenting Author: Yen C

Authors: Yen C, Chen M, Chen Y, Bai L, Chen J,

Keywords: CVM-1118, GEP-NET, anti-vasculogenic mimicry,

#4345 Real-life results of the treatment with lutetium in advanced neuroendocrine tumours

Introduction: Therapy using lutetium-177 dotatate (177LU) was approved in Europe in 2017 for the treatment of advanced neuroendocrine tumours (NETs). Since then, it has become part of the strategies for treating NETs, making it now possible to evaluate real-life results.

Conference:

Presenting Author: Campos Ramírez S

Authors: Campos Ramírez S, Andrés A, Gómez Mugarza P, Blanco Abad C, Monreal Cepero M,

Keywords: Neuroendocrine tumour, Lutetium, Efficacy, Toxicity, Real-Word Evidence,

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#2997 Benefits of 177Lu-DOTATATE in Patients with Advanced Neuroendocrine Tumours: Case Reports from Two Patients with High Disease Burden

Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Wadsley J, Shah T,

Keywords: 177Lu-DOTATATE, metastases, quality of life,